Please try another search
For the fiscal year ended 31 December 2020,Recipharm AB (publ) revenues increased 48% to SEK11.07B.Net income applicable to common stockholders decreased 1%to SEK338.7M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Net income was offset by Employee benefitsexpense increase of 42% to SEK3.66B (expense), Interestexpenses.
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Revenue | 2812.2 | 2582.4 | 3081.2 | 2592.9 |
Gross Profit | 1430.1 | 1224.4 | 1577.8 | 1123.2 |
Operating Income | 339.2 | 192.3 | 339.6 | -65.5 |
Net Income | 222.9 | 46 | 300.1 | -230.4 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Total Assets | 21637.8 | 22511.6 | 22803.9 | 23989.1 |
Total Liabilities | 14283.1 | 14878.7 | 15255 | 18384.9 |
Total Equity | 7354.7 | 7632.9 | 7548.9 | 5604.2 |
Period Ending: | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | 760.3 | 560.5 | 330.4 | -9.2 |
Cash From Investing Activities | -6217 | -6270.4 | -6197.2 | -6052.6 |
Cash From Financing Activities | 5796.5 | 5898.8 | 6133.1 | 6112 |
Net Change in Cash | 248.5 | 156.9 | 234.9 | 89.8 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review